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Abstract. 
 
Vascular endothelial growth factor (VEGF) 
is an important regulator of vasculogenesis, angiogene-
sis, and vascular permeability. In contrast to its tran-
sient expression during the formation of new blood ves-
sels, VEGF and its receptors are continuously and 
highly expressed in some adult tissues, such as the kid-
ney glomerulus and choroid plexus. This suggests that 
VEGF produced by the epithelial cells of these tissues 
might be involved in the induction or maintenance of 
fenestrations in adjacent endothelial cells expressing 
the VEGF receptors. Here we describe a defined in 
vitro culture system where fenestrae formation was in-
duced in adrenal cortex capillary endothelial cells by 
VEGF, but not by fibroblast growth factor. A strong in-
duction of endothelial fenestrations was observed in 
cocultures of endothelial cells with choroid plexus epi-
thelial cells, or mammary epithelial cells stably trans-
fected with cDNAs for VEGF 120 or 164, but not with 
untransfected cells. These results demonstrate that, in 
these cocultures, VEGF is sufficient to induce fenestra-
tions in vitro. Identical results were achieved when the 
epithelial cells were replaced by an epithelial-derived 
basal lamina-type extracellular matrix, but not with col-
lagen alone. In this defined system, VEGF-mediated 
induction of fenestrae was always accompanied by an 
increase in the number of fused diaphragmed caveolae-
like vesicles. Caveolae, but not fenestrae, were labeled 
with a caveolin-1–specific antibody both in vivo and in 
vitro. VEGF stimulation led to VEGF receptor ty-
rosine phosphorylation, but no change in the distribu-
tion, phosphorylation, or protein level of caveolin-1 
was observed. We conclude that VEGF in the presence 
of a basal lamina-type extracellular matrix specifically 
induces fenestrations in endothelial cells. This defined 
in vitro system will allow further study of the signaling 
mechanisms involved in fenestrae formation, modifica-
tion of caveolae, and vascular permeability.
 
F
 
enestrae 
 
are specialized plasma membrane micro-
domains in endothelial cells that are involved in
vascular permeability. They appear as circular dis-
continuities of 
 
z
 
60 nm in diameter and usually occur in
clusters in the most attenuated regions of the endothelial
cell (for review see Palade et al., 1979). Fenestrated endo-
thelia are found in endocrine organs, the gastrointestinal
tract, kidney glomeruli, and specific regions of the brain,
such as choroid plexus, and circumventricular organs, as
well as in many tumors (Rhodin, 1974; Coomber et al.,
1987, 1988; Shibata, 1989; Roberts and Palade, 1997). In
contrast, endothelial cells found within connective tissues,
muscle, skin, lung, and brain generally do not possess fen-
estrations. The molecular basis for this phenotypic diver-
sity of endothelial cells is not known (Risau, 1995).
Previous in vitro studies aimed to identify factors in-
volved in fenestrae formation reported that extracellular
signals (e.g., TGF
 
b
 
, retinoic acid, serotonin), the tumor
promotor phorbol myristate acetate (PMA)
 
1
 
, the actin-dis-
rupting agent cytochalasin B, and calcium ions, as well as
extracellular matrix components, have some effect on
fenestrae formation (Milici et al., 1985; Lombardi et al.,
1986, 1988; Steffan et al., 1987; Carley et al., 1988; McGuire
et al., 1992; Gatmaitan et al., 1996). However, the rele-
vance of these factors in fenestrae induction under physio-
logical conditions in vivo is not known. In addition, no mo-
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lecular markers are available to detect the fenestrated
phenotype in rapid screening assays.
Vascular endothelial growth factor (VEGF), which ex-
ists in several alternative splice variants (Tischer et al.,
1991; Breier et al., 1992; Poltorak et al., 1997), is not only
an endothelial growth factor but was initially character-
ized as a vascular permeability factor secreted by tumor
cells (Senger et al., 1983; Keck et al., 1989). We have previ-
ously shown that VEGF is continuously expressed in epi-
thelial cells of adult organs with fenestrated endothelium,
such as choroid plexus and kidney glomeruli (Breier et al.,
1992). Also, the persistent expression of mRNA for the
corresponding VEGF receptors-1 and -2 in endothelial
cells of these organs has been described (Millauer et al.,
1993; Breier et al., 1995; Simon et al., 1995). Since VEGF
is highly expressed during embryonic vasculogenesis and
angiogenesis, but is downregulated in most adult tissues
when endothelial proliferation has ceased, we speculated
that the continuous expression of VEGF might be in-
volved in the induction or maintenance of endothelial fen-
estrations (Breier et al., 1992). Indeed, it has recently been
shown that VEGF application in vivo directly and rapidly
induced fenestrae in the continuous endothelium of skele-
tal muscle and skin (Roberts and Palade, 1995) and in the
neovasculature of VEGF-secreting tumors (Roberts and
Palade, 1997). Although these studies provide compelling
evidence that VEGF is involved in fenestrae formation in
vivo, in vitro model systems are required to characterize the
molecular mechanisms by which VEGF induces fenestrae.
The exact mechanisms (e.g., transcellular versus para-
cellular) and structures (e.g., plasmalemmal vesicles versus
cell–cell junctions) responsible for increased vascular per-
meability are still controversial (Jain, 1988; Dvorak et al.,
1995; Roberts and Palade, 1997). Compelling evidence ex-
ists that caveolae are involved in transcytotic transport of
solutes across the endothelium (Ghitescu et al., 1986; Pre-
descu et al., 1994, Schnitzer et al., 1994). Caveolae (also
termed plasmalemmal vesicles) are small invaginations at
the cell surface that measure 50–100 nm in diameter and
often surround fenestrae (Palade et al., 1979). It is known
that fenestrae are highly permeable for water and small
solutes (Levick and Smaje, 1987). Electron microscopic
studies have shown that most fenestrae are spanned by a
nonmembraneous diaphragm that is also found in caveo-
lae and in fused clustered vesicles, also referred to as ve-
siculo-vacuolar organelles (VVOs; Dvorak et al., 1996).
However, the exact structural and functional relationship
between these vesicular structures remains unclear.
Caveolin is an integral membrane component of caveo-
lae that is now generally accepted as a marker protein for
this organelle. Caveolin (now termed caveolin-1) belongs
to a multigene family of at least three different members:
caveolin-1, -2, and -3 (Kurzchalia et al., 1992; Way and
Parton, 1995; Scherer et al., 1996; Song et al., 1996; Tang
et al., 1996). Two alternate start sites in the gene of caveo-
lin-1 give rise to 
 
a 
 
and 
 
b 
 
isoforms (Scherer et al., 1995).
The structurally homologous caveolin proteins show over-
lapping but distinct tissue distribution. Although caveolin-1
was found to be a critical component of the caveolar coat
(Rothberg et al., 1992), its function is still unknown. Cave-
olae have been implicated in signal transduction (Ander-
son, 1993; Sargiacomo et al., 1993; Lisanti et al., 1994),
 
transcytosis (Ghitescu et al., 1986; Predescu et al., 1994,
Schnitzer et al., 1994), cholesterol transport (Murata et al.,
1995; Smart et al., 1996), regulation of tissue factor (Mul-
der et al., 1996), and endothelial nitric oxide synthase
function (Garcia-Cardena et al., 1996; Shaul et al., 1996);
(for reviews see also Kurzchalia and Parton, 1996; Parton,
1996; Couet et al., 1997
 
b
 
). Despite the similarity between
caveolae, VVOs, and fenestrae, no information has been
available on the distribution of caveolin-1 in the latter two
structures.
Here we report the establishment of a novel in vitro sys-
tem for studying the conditions under which endothelial
cells develop fenestrations in response to VEGF. Progres-
sively better defined conditions show that VEGF induces
a robust and consistent increase in the number of fenestra-
tions and fused diaphragmed vesicles. This increase was
accompanied by a decrease in labeling of fused vesicles
and fenestrae for caveolin-1, a marker protein of plasmalem-
mal vesicles or caveolae. VEGF stimulation initiated re-
ceptor tyrosine phosphorylation and signal transduction in
endothelial cells. However, no change in phosphorylation
or protein levels of caveolin-1 was observed. Our data
demonstrate that, under defined in vitro conditions, such
as the presence of a basal lamina-type matrix, VEGF is
sufficient to induce fenestrations in vitro.
 
Materials and Methods
 
Materials
 
Laboratory reagents were purchased from Sigma Chemical Co. (Deisen-
hofen, Germany) unless otherwise stated. Anti–caveolin-1 antibodies
were described previously (Dupree et al., 1993) or were purchased from
Santa Cruz Biotechnology, Inc. (C-20; Heidelberg, Germany) or Trans-
duction Laboratories, (C13630; Exeter, UK). For staining of endothelial
cells, a rabbit polyclonal antibody against von Willebrand factor (Dako
Corp., Hamburg, Germany) or monoclonal antibodies against platelet en-
dothelial cell adhesion molecule-1 (Mec 13.3; Vecchi et al., 1994) and en-
doglin (MJ 7⁄18; Ge et al., 1994) were used. Antiphosphoserine and anticy-
tokeratin antibodies were purchased from Sigma Chemical Co. A rabbit
polyclonal serum and a rat monoclonal antibody against flk-1 were gifts
from H. App (SUGEN, Inc., Redwood City, CA), and S.-I. Nishikawa and
H. Kataoke (Kyoto University, Kyoto, Japan), respectively. Antibodies
against phosphotyrosine were obtained from Transduction Laboratories
and the anti-VEGF antibody was prepared as previously described
(Breier et al., 1992). As a control for equal protein loading on gels, a mono-
clonal anti-
 
d
 
-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) anti-
body from Biogenesis (Poole, UK) was used. Peroxidase-conjugated sec-
ondary antibodies (reactive with either rabbit or mouse IgG) were from
Pierce Chemical Co. (Rockford, IL) or Amersham Buchler GmbH
(Braunschweig, Germany). For immunolabeling in light and electron mi-
croscopy, FITC, rhodamine, Cy-3, or gold-conjugated antibodies against
rabbit, mouse, or rat IgG were obtained from The Jackson ImmunoRe-
search Laboratories (West Grove, PA), Amersham Buchler GmbH, or
Aurion (BioTrend, Cologne, Germany). As negative controls for primary
antibodies, unconjugated rabbit, rat, or mouse IgG from Sigma Chemical
Co. and Vector Labs Inc. (Burlingame, CA) were included.
 
Cell Culture
 
Media and other cell culture reagents were obtained from Life Technolo-
gies, Inc. (Eggenstein, Germany). Cloned bovine adrenal cortex endothe-
lial cells (ACE), a gift of J. Folkman (Harvard Medical School, Boston,
MA); Folkman and Haudenschild, 1980) were used at passages 15–20.
Stock cultures were grown on collagen-coated dishes (collagen G; Se-
romed, Berlin, Germany) in low glucose DME containing 10% donor calf
serum (Sigma Chemical Co.). Choroid plexus epithelial cells were isolated
from mice of embryonic day 12.5 (Stadler et al., 1994), cultured on laminin
(Upstate Biotechnology Inc., Lake Placid, NY)-coated dishes, and then 
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routinely checked for expression of cytokeratin by immunofluorescence
microscopy. The mouse mammary epithelial cell lines overexpressing
VEGF 120 or 164 were generated by calcium-phosphate transfection of
EpH4 cells (Oft et al., 1996) with cytomegalovirus-based expression vec-
tors (pRC/CMV; Invitrogen BV, Leek, The Netherlands) that contained
the respective mouse VEGF cDNAs (Breier et al., 1992). Cell clones re-
sistant to G418 (Life Technologies, Inc.) were selected and tested for se-
cretion of the respective VEGF protein into the medium by immunoblot
analysis as published (Breier et al., 1992). Preparation of extracellular ma-
trix–coated dishes was performed essentially as described (Gospodarowicz,
1984). Cocultures were generated by simultaneously seeding epithelial
cells and twice the number of endothelial cells on tissue culture plates that
were either coated for 16 h at 4
 
8
 
C with laminin (cocultures with choroid
plexus epithelial cells) or for 16 h at 37
 
8
 
C with collagen (cocultures with
EpH4 cells). The cells were grown for 
 
z
 
4–7 d in DME supplemented with
10% FCS (PAN Systems GmbH, Nuernberg, Germany) until the cultures
had reached confluency. Human umbilical vein endothelial cells (HU-
VEC) were prepared by the method of Jaffe et al. (1973) as modified by
Jarrell et al. (1984) and then cultured as described in detail elsewhere
(Lampugnani et al., 1992). Human or murine recombinant VEGF was
provided by H. Weich (Gesellschaft für Biotechnologische Forschung,
Braunschweig, Germany), and human basic FGF was obtained from Boeh-
ringer Mannheim (Mannheim, Germany).
 
Electron Microscopy
 
Conventional Microscopy. 
 
Confluent cell monolayers were washed with
Hanks modified salt solution (HMSS), pH 7.4, and then fixed for 4 h in
2% glutaraldehyde (Polysciences Inc., Warrington, PA) in HMSS, pH 7.4,
4
 
8
 
C, followed by two washes in 0.2 M cacodylate buffer for 10 min each
and then postfixed for 1 h in 1% OsO
 
4
 
. After washing, the cells were
scraped from the dishes, centrifuged in buffer for 5 min, and then dehy-
drated by a graded ethanol series. En bloc staining was performed in 6%
uranyl acetate/70% ethanol for 
 
>
 
1 h or overnight in the dark. Samples
were embedded in Araldite (Serva, Heidelberg, Germany), sectioned with
an ultramicrotome (model Ultracut R; Leica, Inc., St. Gallen, Switzer-
land) for electron microscopy, stained with lead citrate, and then exam-
ined in an electron microscope (model EM10; Carl Zeiss, Inc., Thorn-
wood, NY). For morphometric analysis, thin sections were cut for each
specimen from three levels at a distance of 30 
 
m
 
m. In every section, all
profiles of ACE cells, fenestrations, and fused diaphragmed vesicles were
counted. Clusters of diaphragmed vesicles, clusters of fenestrae, and iso-
lated fenestrae were counted as single entities.
 
Immunoelectron Microscopy. 
 
Cell cultures and mouse tissues were
washed in HMSS buffer and fixed in the same buffer supplemented with
2% paraformaldehyde, 0.05% glutaraldehyde, pH 7.4, for 2 h at 4
 
8
 
C. After
washing in PBS, the pellets obtained by centrifugation were enclosed in
2% agar, embedded in Lowicryl K4M resin (Polysciences, Inc., Eppelheim,
Germany), and then polymerized at 
 
2
 
35
 
8
 
C under UV light. Ultrathin sec-
tions were cut and mounted on nickel or copper grids and then immunola-
beled. The sections were blocked for 30 min at room temperature with
TBS containing 5% BSA, 0.1% cold-water fish skin gelatin, 5% normal
serum, and 0.1% Tween-20 (Serva), and then incubated with polyclonal
anti–caveolin-1 antibody (C13630; Transduction Laboratories), diluted 1:100
or 1:50 in incubation buffer: 0.8% BSA, 0.1% cold-water fish skin gelatin,
20 mM NaN
 
3
 
, 0.1% Tween-20 in TBS. As negative controls, the primary
antibody was omitted or nonimmune rabbit IgG at the same concentration
as the primary antibody were used. After washing six times in incubation
buffer, incubation with secondary antibody (goat anti–rabbit conjugated
with 6- or 15-nm gold particles, diluted 1:40 in incubation buffer) was per-
formed. The sections were subsequently washed and postfixed in 2% buff-
ered glutaraldehyde for 5 min. Finally, the grids were washed in distilled
water, air-dried, and then poststained with 6% aqueous uranyl acetate and
lead citrate for 2 min.
 
Indirect Immunofluorescence
 
Cryosections of mouse embryos or adult mouse organs were fixed for 10
min in ice-cold methanol, air-dried, and then blocked for 15 min in normal
goat serum. The sections were incubated for 1 h with the respective pri-
mary antibodies, washed three times with PBS, and then incubated for an-
other hour with the appropriate fluorophore-conjugated secondary anti-
body. After a final wash, the sections were mounted in Mowiol 4-88
(Calbiochem, Bad Soden, Germany). Cells cultured on tissue culture
dishes, glass coverslips, or chamberslides (Nunc, Naperville, IL) were
fixed for 10 min with ice-cold methanol (for cytokeratin- and endothelial-
specific staining) or for 20 min with 3% paraformaldehyde (for caveolin-1
staining), followed by incubation with 50 mM NH
 
4
 
Cl for 10 min and per-
meabilization with 0.2% Triton X-100 for 10 min. The cells were then
rinsed, blocked with normal goat serum, and immunostained as described
above. As negative controls, unconjugated rabbit, rat, or mouse immuno-
globulins were used at the same concentration as the respective primary
antibodies. Fluorescence was examined with a Zeiss Axiophot or Axio-
vert microscope (model 135; Carl Zeiss, Inc.).
 
Immunoprecipitation
 
ACE cells were stimulated with VEGF, pervanadate, or PMA at 37
 
8
 
C as
indicated, pretreated for 1 h with 1 mM vanadate before lysis, and then
washed in PBS containing 1 mM vanadate. The cells were solubilized on
ice for 20 min either in Triton buffer (150 mM NaCl, 10 mM Tris, pH 7.5,
1% Triton X-100) or in SDS lysis buffer (Dupree et al., 1993) supple-
mented with a cocktail of phosphatase and proteinase inhibitors (1 mM
vanadate, 10 
 
m
 
g/ml pepstatin, 10 
 
m
 
g/ml aprotinin, 10 
 
m
 
g/ml leupeptin, 1 mM
PMSF). For serine-phosphorylation studies, buffers additionally con-
tained 400 nM okadaic acid (Calbiochem) and 50 mM NaF. The cells were
scraped from the culture dishes and then the lysates were centrifuged at
13,000 rpm for 10 min at 4
 
8
 
C to pellet cellular debris. The supernatant vol-
ume corresponding to the same number of cells was either subjected to
immunoprecipitation or aliquots were removed and boiled for 5 min after
addition of 4
 
3
 
 sample buffer (Laemmli, 1970). Immunoprecipitations
were performed with antibodies either preabsorbed to protein A– or
G–Sepharose beads (Pharmacia, Freiburg, Germany) or the Sepharose
was added to preformed antibody–antigen complexes. The Sepharose-
bound immune complexes were washed four times with lysis buffer (con-
taining protease and phosphatase inhibitors), once with the same buffers
without detergent, and then boiled in reducing sample buffer.
 
Immunoblotting
 
Conditioned media from control and transfected epithelial cells were con-
centrated using MICROSEP™ microconcentrators (Filtron, Karlstein,
Germany) and then mixed with sample buffer. Proteins of media, total
cellular extracts, and immunoprecipitates were separated by SDS-PAGE
in 7, 12.5, or 15% gels, transferred onto 0.2-
 
m
 
m pore size nitrocellulose
membranes (Schleicher & Schuell, Inc., Dassel, Germany), blocked with
3% BSA in PBST (0.1% Tween-20 in PBS), and then incubated with pri-
mary and peroxidase-conjugated secondary antibodies with six washes of
PBST after each incubation. Protein–antibody complexes were visualized
using the enhanced chemiluminescence Western blot detection system
(Amersham Buchler GmbH).
 
RNA Extraction and Reverse Transcription
(RT)-PCR Analysis
 
Choroid plexus was dissected from bovine brain and then frozen at
 
2
 
80
 
8
 
C. Glomeruli isolated from mouse kidneys (Kurtz et al., 1982) were
stored at 
 
2
 
80
 
8
 
C until used. Total cytoplasmic RNA was isolated from
these tissues using the guanidinium thiocyanate method (Chomczynski
and Sacchi, 1987) and RT was performed essentially as described (Wizig-
mann-Voos et al., 1995) using the following synthetic oligonucleotide
primers for amplification: (5
 
9
 
-oligonucleotide) 5
 
9
 
-d(GTGCTCTCTTG-
GGTGCACTGG), and (3
 
9
 
-oligonucleotide) 5
 
9
 
-d(CACCGCCTTGGCT-
TGTCACAT). As a positive control, cDNAs encoding VEGF 120, 164,
and 188 (Breier et al., 1992) were used as templates for amplification; the
cDNA template was omitted from the reaction as negative control. The
amplification products were separated on 1.5% agarose gels and visual-
ized by ethidium bromide staining.
 
Results
 
Expression of VEGF Isoforms in Organs with 
Fenestrated Endothelium
 
Since different isoforms of VEGF exist, it was conceivable
that one particular isoform might possess the potential bi-
ological activity for induction of fenestrae. Therefore, we
analyzed the expression pattern of VEGF isoforms in dif- 
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ferent adult organs using the RT-PCR technique. RNA
from mouse heart, lung, kidney glomeruli, and bovine
choroid plexus was extracted, reverse transcribed, and
then amplified using different VEGF primer combina-
tions. VEGF isoforms 164 and 120 were predominantly ex-
pressed in choroid plexus (Fig. 1, lane 
 
3
 
) and glomerulus
(data not shown). In lung (Fig. 1, lane 
 
2
 
) and heart (data
not shown), isoform 188 was also detectable. It appears,
therefore, that the presence of VEGF in organs with fen-
estrated endothelium does not correlate with the predomi-
nant expression of a specific VEGF isoform, but may be
related to a persistent VEGF expression in general.
 
Continuous Expression of VEGF and VEGF Receptors 
in Organs with Fenestrated Endothelium
 
We have previously shown by in situ hybridization studies
of embryonic and adult mouse tissues that the expression
of VEGF and its receptors is downregulated in most adult
tissues (Breier et al., 1992; Millauer et al., 1993). In con-
trast, VEGF expression was found to be maintained at a
high level in adult organs with fenestrated endothelium
(Breier et al., 1992; Brown et al., 1992; Jakeman et al.,
1992; Monacci et al., 1993; Simon et al., 1995). For exam-
ple, the mRNA for VEGF and its receptors is highly ex-
pressed in the endothelial cells of embryonic and adult
choroid plexus as well as kidney glomeruli. To study the
requirements for endothelial fenestrations in vitro, we
have examined the choroid plexus in more detail by immu-
nofluorescence microscopy. We found that VEGF recep-
tor-2 (flk-1) was expressed in endothelial cells of embry-
onic and adult choroid plexus (data not shown) also at the
protein level. In addition, the endothelial, but not epithe-
lial, cells of choroid plexus were recognized by antibodies
against caveolin-1 (data not shown). This finding is notable
because high expression of caveolin-1 protein was re-
ported for endothelial as well as epithelial cells (Kurzchalia
et al., 1992; Lisanti et al., 1994). Taken together, these ob-
servations suggested a paracrine role for VEGF expressed
by epithelial cells in the induction or maintenance of fen-
estrations in the adjacent endothelial cells in these tissues.
 
Cocultures of Endothelial Cells with Choroid Plexus 
Epithelial Cells
 
We used an in vitro coculture system in which freshly iso-
lated murine choroid plexus epithelial cells (CPE) were
plated together with bovine ACE. These primary endothe-
lial cells, which express the VEGF receptors-1 and -2
(Plouet and Moukadiri, 1990; Vaisman et al., 1990), are
derived from capillaries that are fenestrated in vivo, but
lose fenestrae in culture (Folkman and Haudenschild,
1980; Furie et al., 1984). Cocultures formed confluent
monolayers in which each cell type tended to grow in iso-
lated clusters, and these were in direct contact with each
other at their border areas (Fig. 2, 
 
a
 
 and 
 
b
 
). Cultures of
each cell type and cocultures were stained with antibodies
against cytokeratin and von Willebrand factor to label epi-
thelial and endothelial cells, respectively. Cultures of pri-
mary CPE cells consisted of 
 
z
 
70% cytokeratin-positive
Figure 1. Expression of VEGF isoforms in bovine choroid
plexus. RT-PCR analysis with VEGF-specific primers of RNA
extracted from bovine or mouse tissues demonstrates predomi-
nant expression of mRNAs for VEGF isoforms 120 and 164 in
choroid plexus (lane 3), whereas the 188 isoform was additionally
expressed in lung (lane 2). The VEGF amplification products of
432-, 564-, and 636-bp correspond to VEGF 120, VEGF 164, and
VEGF 188, respectively. As a positive control, full-length cDNAs
of the three VEGF isoforms were amplified (lanes 4–6). The nega-
tive control without DNA template is shown in lane 1. The iden-
tity of the PCR products was confirmed by Southern blot analysis
with a VEGF-specific probe (data not shown).
Figure 2. Coculture of ACE cells with isolated choroid plexus ep-
ithelial cells. (a) Light micrograph illustrating the difference in
morphology between epithelial and endothelial cells (Ec). (b)
Immunofluorescence staining with an antibody against von Wille-
brand factor of the same microscopic area shown in a. Islands of
labeled endothelial cells within the unlabeled epithelial cell
monolayer can be seen. (c and d) Transmission electron micro-
graphs of ACE cells showing cell contacts and apical–basal mor-
phology (c) and caveolar invaginations at the plasma membrane
(d). (e) ACE cell in coculture with choroid plexus epithelial cells
showing fused clustered vesicles with a diaphragm (arrowhead).
Bars: (a) 100 mm; (c) 1 mm; (d and e) 0.1 mm. 
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epithelial cells. No endothelial cells could be detected with
antibodies against the endothelial-specific antigens von
Willebrand factor, platelet endothelial cell adhesion mole-
cule-1, and endoglin (data not shown). Electron micro-
scopic analysis of ACE cells revealed intact cell–cell junc-
tions and basal–apical polarity (Fig. 2 
 
c
 
). The spindle-like
appearance of these cells also allowed their identification
in coculture. Intercellular contact zones were visible as ar-
eas where either extremely thin processes joined each
other or extensions of larger cytoplasmic areas over-
lapped. In orthograde sections through the middle of the
cell (indicated by the nucleus), relatively few caveolae and
vesicle clusters were attached to the membrane and no dif-
ference in their distribution between the apical and basal
surface was observed. However, in the processes distant
from the perikaryon, the density of caveolae was increased
(Fig. 2 
 
d
 
). Many caveolae were observed to be covered by
a structure reminiscent of a diaphragm. However, fenes-
trations themselves were rarely observed in ACE cells cul-
tured alone. The most striking difference between ACE
cells cultured alone and in cocultures was the appearance
of fenestrations and an increase in the number of fused
vesicles with diaphragms in the endothelial cells (Fig. 2 
 
e
 
).
The fenestrations, which were predominantly found in ex-
tremely attenuated areas of the endothelial cell, displayed
the typical appearance of fenestrae in vivo. They had a di-
ameter of 
 
z
 
60 nm and were bridged by a thin diaphragm,
which sometimes contained a central knob (see also Fig.
4). We conclude that CPE cells are able to induce endo-
thelial fenestrations in vitro. Since CPE cells produce
VEGF in vivo, we asked whether VEGF itself, in an epi-
thelial context, induces fenestrae.
 
Cocultures of Endothelial Cells with Stably Transfected 
Epithelial Cell Lines Overexpressing VEGF
 
To determine the direct effects of VEGF produced by epi-
thelial cells on ACE cells, we used a mouse epithelial cell
line (EpH4; Oft et al., 1996) that was stably transfected
with either VEGF 164 or 120, as these were the two main
isoforms found to be expressed in organs with fenestrated
endothelium (refer to Fig. 1). Untransfected and VEGF-
transfected epithelial cells displayed the typical cobble-
stone appearance of squamous epithelia with extensive
tight junctions (data not shown). Immunoblot analysis of
conditioned EpH4 media revealed that untransfected
EpH4 cells exhibited only a very low basal expression of
VEGF, whereas the transfected cell lines secreted high
levels of the respective VEGF isoforms (Fig. 3 
 
a
 
). VEGF
120–transfected cells produced a higher amount of VEGF
protein than VEGF 164–transfected cells (Fig. 3 
 
a
 
). The
morphological appearance of the coculture was similar to
the CPE/ACE cocultures, showing separate islands of
tightly clustered cobblestone-shaped epithelial cells and
spindle-shaped endothelial cells (Fig. 3, 
 
b
 
 and 
 
c
 
). Growth
of both epithelial and endothelial cells appeared to be ac-
celerated in cocultures. Overexpression of VEGF by the
transfected epithelial cells had a morphological effect on
neighboring ACE cells, which was already visible at the
light microscopic level. As illustrated in Fig. 3 
 
c
 
, ACE cells
in cocultures with the transfected epithelial cells had a
more elongated phenotype and developed small branches
and sprouts, which were often concentrated in areas of en-
dothelial cell islands close to epithelial cells. These were
not observed in cocultures with untransfected cells. Elec-
tron microscopy of cocultures with transfected cells re-
vealed an induction of fenestrae and a strong increase in
the number of fused diaphragmed vesicles (Fig. 3, 
 
d–f
 
).
Figure 3. Cocultures of ACE cells with epithelial cells trans-
fected with VEGF. (a) Transfected epithelial cells secrete VEGF
into the medium. Conditioned media of normal and transfected
epithelial cells were subjected to immunoblot analysis using anti-
VEGF antibodies recognizing all known mouse VEGF isoforms.
EpH4 cells stably transfected with cDNAs for VEGF 120 and 164
(lanes 2 and 4) secrete high levels of VEGF 120 (open arrow-
head) and 164 (closed arrowhead) into the medium when com-
pared to untransfected control cells (C; lanes 1 and 3). The broad
band around 60 kD corresponds to the mol wt of BSA. (b and c)
Light micrographs of cocultures of ACE cells with EpH4 cells,
which were either untransfected (b) or transfected with the
cDNA for VEGF 120 (c). The endothelial cells (Ec) appear to be
more elongated and have developed small branches and sprouts
(arrowheads) in cocultures with transfected EpH4 cells. (d–f)
Electron micrographs showing sections through ACE cells cocul-
tivated with VEGF 120–transfected epithelial cells. (d) Fenestrae
(arrowheads) are arranged similarly to the in vivo situation in ex-
tremely attenuated areas of the endothelial cell. (e) Vertical sec-
tion through a cellular process. Note fused clustered vesicles
(bracket) combined with a dilated transendothelial channel (ar-
rowheads) surrounding a larger vacuole. (f) Clusters of dia-
phragmed vesicles (brackets) and fenestrae (arrowheads) in ACE
cells are shown. Bars: (b and c) 100 mm; (d) 0.25 mm; (e and f)
0.1 mm.The Journal of Cell Biology, Volume 140, 1998 952
Frequently, fenestrae were found in thin processes of en-
dothelial cells, thus resembling their appearance in vivo
(Fig. 3 d). In addition, extremely thin cellular extensions
enclosing an extracellular space or cellular process also ex-
hibited numerous fenestrations (Fig. 3 f).
To quantify the effect of VEGF on ACE cells, a mor-
phometric analysis was performed by counting the number
of fenestrations and fused clustered vesicles with dia-
phragms and then expressing them in relation to the num-
ber of cellular profiles. Table I summarizes the quantita-
tive effect of VEGF in cocultures of epithelial and
endothelial cells. VEGF120-overexpressing EpH4 cells in-
duced a seven- or eightfold increase in the number of
fused clustered vesicles and fenestrae in ACE cells. The
induction was less pronounced in cocultures with the
VEGF 164–transfected cells, which may be attributed to
the lower amount of VEGF secreted by this cell line.
There was only a minor effect on fenestrae induction in
cocultures with untransfected EpH4 cells compared to
monocultures of ACE cells, which may be explained by
the low basal expression of VEGF in control EpH4 cells.
Taken together, these data demonstrate that VEGF in-
duces an increase in the number of endothelial fenestra-
tions and fused diaphragmed vesicles in vitro. In experi-
ments where cocultures of transfected EpH4 cells with
HUVEC instead of ACE cells were used, no effect was ob-
served (data not shown).
Effect of Purified VEGF on Endothelial Cells Grown on 
Complex Extracellular Matrix
To test the possibility that additional factors produced by
the epithelial cells synergize with VEGF in fenestrae in-
duction, we further reduced the complexity of our in vitro
system and tested the effect of purified VEGF on endo-
thelial cells. Since the importance of a specific extracellu-
lar environment for fenestrae induction had been demon-
strated (Milici et al., 1985; Carley et al., 1988; McGuire et al.,
1992), we tested the contribution of different extracellular
matrices to the effect of VEGF. We cultivated the endo-
thelial cells either on rat tail collagen, which is a mixture of
type I and III collagen, or on a basal lamina-type extracel-
lular matrix produced by corneal endothelial cells. We
then incubated the cells for various time periods with re-
combinant VEGF 165 using concentrations (50–100 ng/ml)
known to maximally induce autophosphorylation of VEGF
receptors (Waltenberger et al., 1994). Similar to the cocul-
tures, purified VEGF induced an elongated endothelial
phenotype and the appearance of cell sprouts, which were
first visible after 6 h of incubation and were much more
pronounced after a 24-h treatment (data not shown). Elec-
tron microscopical analysis of ACE cells cultured on basal
lamina-type matrix and stimulated for 24 h with VEGF re-
vealed an increase in the number of fused diaphragmed
vesicles and fenestrations to a similar extent as in the co-
cultures (Fig. 4; Table II). ACE cells formed long thin cel-
lular processes, which were interrupted by numerous fen-
estrations (Fig. 4, a and b). In addition, large clusters of
fused vesicles were found, frequently separated only by
thin diaphragms that often contained a central knob (Fig.
4 c). Incubation periods shorter than 24 h did not show an
effect on fenestrae formation. Consistent with the cocul-
ture studies, VEGF induced fenestrae formation only two-
or threefold in HUVEC cells cultivated on the matrix
(data not shown). As a control for the extracellular matrix
effect, parallel cultures of ACE cells were plated on rat tail
Table I. Fenestrae Induction in Cocultures
Culture
[Fenestrae 1 clustered
vesicles]/cell (mean) SD
ACE 0.0189 0.0033
ACE 1 EPH4 0.0229 0.0042
ACE 1 EPH4/VEGF 164 0.1231 0.0500
ACE 1 EPH4/VEGF 120 0.1444 0.0632
Endothelial fenestrations and clustered diaphragmed vesicles in ACE cells in cocul-
ture with mouse mammary epithelial cells. Diaphragmed fenestrations and clustered
vesicles were counted in z330 (ACE), 400 (ACE 1 EpH4), 390 (ACE 1 EpH4/
VEGF164), and 540 cells (ACE 1 EpH4/VEGF120) using sections from two indepen-
dent experiments. Results were obtained from three section levels cut at a distance of
30 mm as described in Materials and Methods. The ratios of diaphragmed clustered
vesicles and fenestrae number per cell profile were then determined. Student’s t test
was applied for pairwise comparison of the data and showed P , 0.001 for ACE ver-
sus ACE 1 EpH4/VEGF164; P , 0.005 for ACE versus ACE 1 EpH4/VEGF120;
and P , 0.05 for ACE 1 EpH4 versus ACE 1 EpH4/VEGF120.
Figure 4. Electron micrograph of ACE cells cultured on basal-
lamina type extracellular matrix after a 24-h treatment with
VEGF. (a) ACE cells form long thin cellular processes that are
interrupted by numerous fenestrations (arrowheads). (b) The en-
dothelial cell is still connected to the underlying extracellular ma-
trix (M). Fenestrations (arrowheads) are bridged by thin dia-
phragms, which sometimes contain a central knob (arrows). (c)
ACE cell with a cluster of fused vesicles, which are separated
only by thin diaphragms with a central knob (arrows). Bars: (a
and b) 0.2 mm; (c) 0.1 mm.Esser et al. VEGF Induces Fenestrae 953
collagen. VEGF treatment of cells under these conditions
did not induce fused vesicles and fenestrations, whereas
ACE cells cultured on the basal lamina-type matrix
showed a 10-fold increase (Table II). Since basic FGF has
also been reported to induce fenestrae in vivo (Roberts
and Palade, 1997), we tested if it could replace VEGF in
our in vitro system. However, incubation of ACE cells cul-
tured on basal lamina-type matrix with basic FGF had
only a minor effect on the number of fenestrations and
fused diaphragmed vesicles (Table II). In conclusion, our
data show that the effect of VEGF on fenestrae induction
in vitro is specific. In addition, in the presence of a basal
lamina-type matrix, VEGF is also sufficient for the induc-
tion of fenestrations in ACE cells in vitro.
Caveolae, but Not Fenestrae or Fused
Diaphragmed Vesicles, Can Be Labeled with Antibodies 
against Caveolin-1
Since the induction of endothelial fenestrations by VEGF
was always accompanied by an increase in the number of
fused clustered caveolae-like vesicles with diaphragms, we
wondered if caveolar proteins might be common molecu-
lar components of these structures. Ultrathin Lowicryl sec-
tions of paraformaldehyde-fixed material were labeled
with an antibody against caveolin-1, a marker protein of
caveolae. We first confirmed the specificity of our ap-
proach by in situ labeling of mouse muscle capillaries,
which have continuous endothelia extremely rich in caveo-
lae. As shown in Fig. 5 a, a considerable fraction of the ca-
veolae were immunolabeled with the antibody. The label-
ing efficiency was increased in cryosections compared to
resin sections (data not shown). No labeling was seen if the
primary antibody was omitted or replaced by nonimmune
rabbit immunoglobulins (Fig. 5 b). Caveolin-1–positive
vesicles could also be identified in endothelial cells of the
choroid plexus dissected from adult mouse brain (Fig. 5 c).
In contrast, the fenestrae of these endothelial cells were al-
ways devoid of anti–caveolin-1 immunoreactivity (Fig. 5 c).
In vitro, we analyzed the cocultures of VEGF-trans-
fected epithelial cells that had shown a strong induction of
fenestrae and fused clustered vesicles. Fig. 5 d shows spe-
cific labeling of endothelial caveolae with anti–caveolin-1
antibodies in ACE cells. Specific labeling was only found
in uncoated vesicles of apical or basal plasma membranes
and was absent in control experiments when the first anti-
body was omitted. EpH4 cells revealed some immunoposi-
tive caveolae in their lateral membranes (data not shown).
We never detected caveolin-1 in diaphragmed fenestra-
tions (Fig. 5 f). Except for one gold particle, which may
represent a recently fused caveola (Fig. 5 e), clustered dia-
phragmed vesicles were found to be immunonegative for
caveolin-1.
Effects of VEGF on Caveolin-1 Expression and 
Phosphorylation in ACE Cells
Since caveolin-1 was detected in endothelial caveolae, but
not in fused clustered vesicles or fenestrae, we asked
whether caveolin-1 is modified as a possible downstream
target of VEGF signal transduction. We incubated ACE
cells cultured on the basal lamina-type matrix for various
time points with VEGF and performed immunoprecipita-
tions with an antibody against VEGF receptor-2 and the
anti–caveolin-1 antibody VIP-21N, which only recognizes
the a isoform. VEGF rapidly induced the tyrosine phos-
phorylation of a 205-kD band, which was identified as the
bovine form of the VEGF receptor-2 (Fig. 6 a), confirming
the initiation of VEGF-induced signal transduction path-
ways in ACE cells. However, phosphorylation of caveolin-1
on tyrosine (Fig. 6 b) or serine residues (data not shown)
was not observed at any time after VEGF treatment. As a
control, treatment of ACE cells with the tyrosine phos-
phatase inhibitor pervanadate led to tyrosine phosphory-
lation and association of caveolin-1 with other phospho-
proteins with molecular masses of z70, 30, 26, and 24-kD
(Fig. 6, c and d; Vepa et al., 1997). In contrast to immuno-
fluorescent labeling of caveolin-1 after pervanadate treat-
ment, ACE cells stimulated with VEGF did not differ in
caveolin-1 distribution compared to control cells (data not
shown). Since we had observed that the number of fused
caveolae-like vesicles increased in response to a longer
treatment with VEGF, we tested if the amount of caveo-
lin-1 protein was altered in these experiments. However,
no change was observed in the expression level of caveo-
lin-1 protein after treatment with VEGF, pervanadate, or
PMA (Fig. 7). Taken together, our biochemical and immu-
nofluorescence analyses demonstrate that induction of
fenestrae in ACE cells in response to VEGF is not accom-
panied by a change in caveolin-1 phosphorylation, expres-
sion, or distribution.
Discussion
VEGF was first identified as a vascular permeability fac-
tor. After cloning murine VEGF and analyzing its distri-
bution by in situ hybridization, we observed a strong cor-
relation of VEGF expression with angiogenesis during
embryonic development, e.g., in the brain (Breier et al.,
1992). However, we found a continuous expression in epi-
thelial cells of the choroid plexus and kidney glomerulus
(podocytes) throughout development into the adult. Since
the closely associated endothelial cells of these structures
were fenestrated and also constitutively expressed VEGF
receptors (Millauer et al., 1993; Breier et al., 1995), we
speculated that VEGF might be involved in the induction
Table II. Effects of Extracellular Matrix and Growth Factors
Culture
[Fenestrae 1 clustered
vesicles]/cell (mean) SD
ACE/ECM 0.0157 0.0064
ACE/ECM 1 VEGF 165 0.1636 0.0121
ACE/ECM 1 bFGF 0.0372 0.0094
ACE/collagen 0.0077 0.0022
ACE/collagen 1 VEGF 165 0.0033 0.0057
ACE cells were grown to confluency and then VEGF 165 (100 ng/ml) or bFGF (20
ng/ml) were added to the medium. After 24 h the cells were fixed and processed for
electron microscopy. Diaphragmed fenestrations and clustered vesicles were then
counted in 370 (ACE/ECM), 630 (ACE/ECM 1 VEGF165), 540 (ACE/ECM 1
bFGF), 415 (ACE/collagen), and 500 cells (ACE/collagen 1 VEGF165). The number
of clustered vesicles and fenestrae in ACE cells grown on the complex matrix and
stimulated with VEGF is comparable to that of cocultures of ACE cells with trans-
fected epithelial cells (compare Tables I and II) and highly significant (P , 0.001). In
contrast, bFGF has only a minor effect (P , 0.05) on fenestrae and clustered vesicles,
whereas ACE cells grown on collagen were not inducible.The Journal of Cell Biology, Volume 140, 1998 954
or maintenance of endothelial fenestrations. This has been
recently demonstrated in vivo by Roberts and Palade
(1995, 1997) who showed that topical administration of
VEGF 165 induced fenestrations in continuous microvas-
cular endothelium of muscle and skin, and that tumor
neovasculature induced by VEGF is fenestrated. How-
ever, in these in vivo systems, the questions regarding the
responsible VEGF isoforms, the roles of contributing fac-
tors, supporting cells, and extracellular matrix are difficult
to address. Biochemical studies on signal transduction and
changes in molecular composition are almost impossible
to perform in vivo due to tissue complexity and lack of suf-
ficient material. Therefore, an in vitro system to study the
effects of VEGF on fenestrae induction would be valuable.
To develop an in vitro system, we first used CPE in cocul-
ture with ACE. Wilting and Christ (1989) have demon-
strated that grafting of CPE from quail into the coelomic
cavity of chicken embryos induced the differentiation of
fenestrated capillaries in vivo. In our in vitro cocultures of
ACE cells with CPE, we also observed a strong induction
of fenestrae. This prompted us to develop a system in
which the direct effects of VEGF could be analyzed. We
used a mammary epithelial cell line that by itself secreted
very little endogenous VEGF under normal culture condi-
Figure 5. Immunoelectron mi-
croscopy using anti–caveolin-1
antibody. (a) Many caveolae
are labeled with gold parti-
cles in mouse skeletal muscle
capillaries. (b) Controls show
no labeling for caveolin-1. (c)
In capillaries of the choroid
plexus, caveolin-1 labeling is
found in caveolae but not in
fenestrations (arrowheads).
(d–f) Electron micrographs
of ACE cells cocultured with
VEGF 120–transfected epi-
thelial cells. (d) Tangential
section of an endothelial cell
showing labeling of caveolae.
(e) Tangential section through
a grape-like cluster of dia-
phragmed vesicles. Only one
vesicle is labeled (arrow). (f)
Endothelial cell processes
with multiple unlabeled fenes-
trae (arrowheads) and several
gold-labeled caveolae (arrows).
Capillary lumina are indicated
by an asterisk. MC indicates
muscle cell. Bars: (a–d and f)
0.2 mm; (e) 0.1 mm.Esser et al. VEGF Induces Fenestrae 955
tions. Epithelial cells stably transfected with VEGF cDNAs
secreted a high level of VEGF and induced a seven- or
eightfold increase in fenestrae and fused clustered vesicles
in cocultured endothelial cells, thus providing direct evi-
dence for a role of VEGF in fenestrae induction.
Using a complex basal lamina-type extracellular matrix,
we showed that the addition of purified recombinant
VEGF, but not bFGF, was sufficient to induce a ten-fold
increase in fenestrations in endothelial cells. These pro-
gressively better-defined in vitro systems demonstrate for
the first time that VEGF is a specific inducer of fenestra-
tions in vitro. The fact that FGF has no major effect on
fenestrae induction is interesting, because previous in vivo
experiments have noted some effect of FGF (Roberts and
Palade, 1997). In agreement with the hypothesis of these
authors, we would suggest that FGF acts indirectly by up-
regulating VEGF or its receptors in the complex in vivo
situation, but is unable to directly induce fenestrations in
the defined in vitro system.
VEGF 120 and 164 induced fenestrations. Both isoforms
are expressed in organs with fenestrated blood vessels
(Bacic et al., 1995; Simon et al., 1995; this report) and bind
to the high-affinity VEGF receptors-1 and -2 (Gitay-
Goren et al., 1996; Keyt et al., 1996) that are expressed in
endothelial cells of choroid plexus, kidney glomeruli, and
cultured ACE cells (Plouet and Moukadiri, 1990; Vaisman
et al., 1990; Millauer et al., 1993; Breier et al., 1995; Simon
et al., 1995; this report). So far, different VEGF isoforms
have not been observed to exhibit different biological
effects (Birkenhager et al., 1996; Wilting et al., 1996;
Schmidt and Flamme, 1997), although it was reported that
VEGF 165 has an increased affinity for VEGF receptor-1
and a higher mitogenic potency compared to VEGF 121
(Keyt et al., 1996). In any case, our results imply a role for
the VEGF isoforms 120 and 164 in fenestrae induction.
In addition to fenestrae formation, a striking induction
of fused clustered caveolae-like vesicles with diaphragms
was observed after VEGF treatment. Dilated plasmalem-
mal vesicles that aggregate to form clusters in which the
vesicles are fused to one another and are separated by dia-
phragms provided with central knobs (Roberts and Palade,
1995) have also been referred to as VVOs (Kohn et al.,
1992). VVOs have been observed in a small portion of
normal venules in vivo (Feng et al., 1996), but seem to oc-
cur consistently in tumor vessels (Kohn et al., 1992; Qu et
al., 1995). The function of VVOs was shown to be acti-
vated after treatment with VEGF in vivo (Feng et al.,
1996). VEGF has also been localized to VVOs in tumor-
associated microvascular endothelial cells (Qu et al., 1995).
Considering the morphological relationship among VVOs,
plasmalemmal vesicles, and endothelial fenestrations (e.g.,
Figure 6. VEGF-induced signal transduction does not stimulate
tyrosine phosphorylation of caveolin-1. (a) Tyrosine phosphory-
lation of bovine VEGF receptor-2 (flk-1) in ACE cells after
VEGF stimulation. Endothelial cells were stimulated with (1) or
without (2)100 ng/ml VEGF 165 for 5 min, extracted with Triton
buffer, and then immunoprecipitated with anti–flk-1 antibodies.
The precipitates were analyzed by Western immunoblotting with
an antibody against phosphotyrosine (top). The same membrane
was afterwards reprobed with an antibody recognizing flk-1 (bot-
tom). In contrast to unstimulated cells (lane 1) bovine flk-1 (ar-
rowhead) is found to be specifically phosphorylated on tyrosine
after VEGF treatment (lane 2). (b) VEGF does not induce cave-
olin-1 tyrosine phosphorylation. ACE cells grown on basal lam-
ina-type extracellular matrix were stimulated with VEGF 165 for
the indicated time, extracted with SDS lysis buffer, immunopre-
cipitated with VIP-21N antibody, and then subjected to immuno-
blot analysis with antiphosphotyrosine antibody (top). Subse-
quent reprobing of the same membrane with anti–caveolin-1
antibody (bottom) indicated that equal amounts of caveolin-1 (ar-
rowhead) have been precipitated. Protein bands at 50 and 30–25
kD corresponding to the IgG heavy and light chains eluted from
the Sepharose, together with the bound proteins, are also present
in immunoprecipitations without cell lysates (top, lane 8). (c and
d) Pervanadate-induced tyrosine phosphorylation of caveolin-1
and associated proteins. ACE cells were treated with (1) or with-
out (2) pervanadate (PV), extracted with SDS lysis buffer, and
then subjected to immunoprecipitation with antibodies against
caveolin-1 (c) or phosphotyrosine (d), followed by Western
immunoblotting with antiphosphotyrosine (c, top) or anticaveo-
lin-1 (d) antibodies. Blots of caveolin-1 immunoprecipitates were
reprobed with anti–caveolin-1 antibody (c, bottom). The bands at
50 and 30–25 kD correspond to the IgG heavy and light chains.
To reveal all precipitated phosphoproteins, two different expo-
sures for the antiphosphotyrosine blots are shown in c. Note that
the anticaveolin-1 antibody detects only one band in antiphos-
photyrosine- and anti–caveolin-1 precipitates (c and d, arrows),
whereas the antiphosphotyrosine antibody recognizes several
proteins in the anticaveolin-1 precipitates (c, top arrowheads). As
controls, immunoprecipitations without cell lysates (lanes 1 in c
and d) and total cellular extracts (d, lane 4) are shown.The Journal of Cell Biology, Volume 140, 1998 956
size, presence of diaphragms, and cholesterol dependence)
and the ocurrence of endothelial fenestrations as clusters
in vivo, we decided to count clustered fenestrae and clus-
tered diaphragmed vesicles together. By analyzing more
than 4,500 cellular profiles in transmission electron mi-
croscopy, these structures appeared to be interrelated, but
the exact temporal and spatial determinants of their for-
mation is presently unclear. However, these observations
raise the important question of whether caveolae can fuse
and give rise to VVOs, and if subsequent VVOs can give
rise to the so-called sieve plates (clusters of fenestrae found
in the most attenuated periphery of endothelial cells).
Very little is known about the structural composition
and modulation of caveolae, VVOs, and fenestrae. Caveo-
lin-1 is a commonly accepted marker protein for caveolae
(Rothberg et al., 1992; Parton et al., 1994; Smart et al.,
1994, Stan et al., 1997). We attempted to correlate the dis-
tribution and biochemical modification of caveolin-1 with
the distribution and induction of caveolae, fenestrae, and
VVOs in vivo and in vitro. A considerable fraction of ca-
veolae in endothelial cells of tissues and cocultures could
be labeled with anti–caveolin-1 antibodies in immunoelec-
tron microscopy. Clustered diaphragmed vesicles were
only very rarely labeled and all fenestrae were negative for
caveolin-1, suggesting that caveolin-1 may be specifically
excluded from fused clustered vesicles and fenestrae.
Therefore, it was interesting to investigate if modification
of caveolin-1 after VEGF treatment correlated with the
induction of fused clustered vesicles and fenestrae. VEGF
did not induce a change in caveolin-1 distribution, tyrosine
or serine phosphorylation, or alteration in the protein
level of caveolin-1. A change in the distribution of caveo-
lin-1 was observed only after pervanadate stimulation that
caused increased tyrosine phosphorylation of caveolin-1
and associated proteins. Our results on tyrosine and serine
phosphorylation of caveolin-1 are consistent with previous
studies that demonstrated the activation of signaling in ca-
veolae after stimulation with EGF, PDGF, or insulin in
the absence of a consistent change in caveolin-1 phosphor-
ylation (Scherer et al., 1994; Mastick et al., 1995; Liu et al.,
1996). Although the induction of tyrosine phosphorylation
of caveolin-1 after pervanadate treatment has been shown
before (Vepa et al., 1997), the nature of the coprecipitated
phosphoproteins and their possible relationship to previ-
ously identified caveolin-1–associated proteins (Scherer
et al., 1994; Mastick et al., 1995; Liu et al., 1996) remains to
be established. Whether VEGF receptors are concen-
trated in caveolae, as has been shown for PDGF receptor
(Liu et al., 1996, 1997), EGF receptor (Smart et al., 1995), as
well as other tyrosine kinase receptors (Wu et al., 1997), is
not yet known, but is strongly suggested by the presence of
a consensus binding site (WSF/YGVLLWEIF) for the ca-
veolin-scaffolding domain (Couet et al., 1997a) in their cy-
toplasmic tails. It is controversial whether caveolin-1 is
regulated at the protein level (Glenney, 1989; Koleske et
al., 1995; Mineo et al., 1996). Since we did not observe ma-
jor changes in the amount of caveolin-1 protein after
VEGF stimulation, the subcellular localization of caveo-
lin-1 may be altered without concomitant protein degrada-
tion or synthesis. Several possibilities such as different ca-
veolin-1 conformations or modifications not recognized by
the available antibodies remain to be tested. Alternatively,
palmitoylation or the oligomerization properties of caveo-
lin-1 might be altered after VEGF treatment (Monier et
al., 1995, 1996). However, the most likely explanation is
that fusion of clustered caveolae-like vesicles leading to
VVOs and fenestrae is accompanied by a loss of caveolin-1
protein. These observations suggest that although caveo-
lin-1–coated vesicles might be involved in the formation or
recruitment of fused diaphragmed vesicles and fenestrae,
they do not comprise a structural entity of fenestrae them-
selves.
Previous in vivo experiments have shown that applica-
tion of VEGF induced fenestrae in capillaries of skeletal
muscle and skin (Roberts and Palade, 1995). Muscle and
skin endothelial cells contain the highest number of caveo-
lae and are sometimes found to be fenestrated (Kornelius-
sen, 1975; Wolff, 1977). Therefore, it is possible that
VEGF induces fenestrations only in an in vivo or in vitro
environment that is permissive for fenestrae formation.
One prerequisite for fenestrae formation seems to be a
certain threshold number of caveolae. Brain microvessels
have the lowest number of caveolae (Coomber and Stew-
art, 1985), and may be the least inducible endothelial cells.
However, endothelial cells in the early embryonic perineu-
ral vascular plexus are fenestrated (Yoshida et al., 1988)
and the neovasculature of some VEGF-secreting brain tu-
mors has been found to possess endothelial fenestrations
(Roberts and Palade, 1997). Fenestrated bovine ACE lose
fenestrae when cultured (Folkman and Haudenschild,
1980; Furie et al., 1984), probably due to the withdrawal of
VEGF-producing adrenal cortex epithelial cells. These
previously fenestrated cells are the most responsive cells
in terms of fenestrae inducibility analyzed in vitro so far.
We have observed some, though weak, induction of fenes-
trations in HUVEC cells in vitro. Therefore, VEGF is able
Figure 7. VEGF does not alter the level of caveolin-1 protein.
ACE cells were grown on basal-lamina matrix and treated with
(a) VEGF 165 for the indicated time or (b) with pervanadate
(PV, 20 min) or PMA (200 ng/ml, 1 h). Total cellular extracts
were subjected to SDS-PAGE and immunoblot analysis with
anti–caveolin-1 antibodies (top). The amount of caveolin-1 did not
change after stimulation with VEGF, pervanadate, or PMA. Sub-
sequent probing of the same membrane with anti-GAPDH anti-
body indicates equal amounts of protein in each lane (bottom).Esser et al. VEGF Induces Fenestrae 957
to induce fenestrae in previously nonfenestrated endothe-
lial cells, but the magnitude of the response seems to be
dependent on the origin of the endothelium. It is conceiv-
able that, in contrast to embryonic endothelium that seems
to be more plastic, the responsiveness of adult endothe-
lium is restricted by the counteractive effects of the sur-
rounding microenvironment, e.g., within the brain, to
maintain blood–brain barrier and low permeability prop-
erties (Risau, 1995).
The other prerequisite for fenestrae formation seems to
be an appropriate three-dimensional architecture of the
endothelial cell. We demonstrate here that, in our in vitro
system, the induction of fenestrae is completely dependent
on a basal lamina-type extracellular matrix, because ACE
cells cultured on collagen in the presence of VEGF were
virtually devoid of fenestrations. These data are supported
by our in vivo experiments of retroviral overexpression of
VEGF in which we have rarely seen endothelial fenestrae
in hypervascularized embryonic tissue (Flamme et al.,
1995), and are consistent with the observation that an in-
tact basal lamina forms rather late in vascular develop-
ment (Risau and Lemmon, 1988). Therefore, both the cor-
rect extracellular matrix as well as activation of the
relevant receptor seem to be necessary for the formation
of fenestrae in endothelial cells. In vivo as well as in vitro,
fenestrae are located in extremely attenuated regions of
endothelial cells and are often organized as sieve plates.
The first morphological effect observed in VEGF-treated
endothelial cell cultures was the appearance of branch-like
cell sprouts already visible after 6 h of stimulation. These
thin cellular extensions also contained an extremely high
density of caveolin-1 protein (data not shown). VEGF
binding to and activation of its receptors may induce both
the flattening of cellular processes and insertion of fenes-
trations. However, formation of cellular processes was
also seen with bFGF (data not shown). Hence, it is unclear
if this morphological change is associated with fenestrae
induction or rather represents a general effect of VEGF
and other growth factors on ACE cells.
Although the morphological characteristics and pres-
ence of fenestrae in specific vascular beds has been care-
fully analyzed, the molecular composition, induction, and
maintenance of fenestrations in endothelial cells is still not
well understood. Physiological studies have shown that
fenestrae provide highly permeable pores for water and
small solutes. More recently, based on the high density of
cationic ferritin labeling of fenestrae, the anionic glyco-
calix present in fenestral pores has been investigated in
more detail and shown to consist of filamentous plugs
(Rostgaard and Qvortrup, 1997). However, this anionic
coat may be quite variable, and even absent, in certain
capillaries, e.g., in tumors (Roberts and Palade, 1997).
These results raise the possibility that the permeability of
endothelial fenestrations is not uniform but differs de-
pending on the presence or absence of diaphragms, fila-
mentous plugs, or the composition of the anionic glyco-
calix. Further insights into the functional heterogeneity of
vascular territories in terms of permeability clearly require
a molecular definition of fenestrae, diaphragms, caveolae,
fused clustered caveolae-like vesicles, and VVOs. The
availability of our in vitro system for fenestrae induction
allows several important issues to be addressed, e.g., which
signal transduction systems in endothelial cells are in-
volved in the formation of cellular processes and fenes-
trae, and how the signals from VEGF receptor–tyrosine
kinases are integrated with the putative integrin signals af-
ter their binding to the basal lamina-type extracellular ma-
trix. Furthermore, the activity of VEGF as an endothelial
growth versus permeability/fenestrae-inducing factor must
be differentially regulated. It is conceivable that the
VEGF-secreting epithelial cells induce a similar cascade of
signals in the closely associated endothelial cells as re-
quired for growth and migration. However, the complex
basal lamina and components therein, e.g., inhibitors, may
modulate the signal so that no new capillaries form. This is
consistent with the notion that epithelia are resistant to
vascular invasion. The establishment of our in vitro system
of endothelial fenestrations promises to be a useful model
to further clarify the molecular mechanisms that are in-
volved in the formation and function of endothelial fenes-
trations.
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